Vitro Diagnostic Tests (SAHPRA approved)
The Capebio™ SARS-CoV-2 Singleplex RT-qPCR kit is a RT-qPCR ReadyMix™ Kit. It contains the Mutant Reverse Transcriptase, Cod Uracil-DNA Glycosylase and Taq DNA polymerase enzymes that are optimised for convenient generation of complimentary DNA and its subsequent amplification in a single tube. The kit is specific for in vitro detection of SARS-CoV-2 RNA, which is extracted from human clinical samples (i.e., nasopharyngeal, and oropharyngeal swabs) from patients suspected of having COVID-19 by healthcare providers. The kit utilizes the World Health Organization (WHO) recommended primer and probe sets. The kit comes with custom-made Applied Biosystems™ TAQMAN® QSY™ probes. The assay is compatible with Applied Biosystems’s MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit (cat no. A42352). There are no recorded incompatibilities with existing RNA extraction kits.
| Catalogue no | COVRT0500 | COVRT1000 |
| Number of reactions | 500 | 1000 |
| CapeEnzymes ReadyMix™ (consists of mutant reverse transcriptase, UDG-cod and CapeSprint™ Taq DNA polymerase) | 1500 μL | 3000 μL |
| CapeBuffer 10X ReadyMix™ (consists of optimized reaction buffer & dNTPs) | 1750 μL | 3500 μL |
| SARS-CoV-2_N-Gene Primers/Probe ReadyMix™ (Reporter: VIC; Quencher: QSY) | 1200 μL | 2400 μL |
| SARS-CoV-2_S-Gene Primers/Probe ReadyMix™ (Reporter: ABY; Quencher: QSY) | 750 μL | 1500 μL |
| SARS-CoV-2_Human RNaseP_Forward Primers/Probe ReadyMix™ (Reporter: ABY; Quencher: QSY) | 1200 μL | 3500 μL |
| SARS-CoV-2 Positive Control (Plasmid DNA) | 40 μL | 80 μL |
| Nuclease-Free Water | 2000 μL | 4000 μL |
The Capebio™ SARS-CoV-2 Multiplex RT-qPCR kit is a RT-qPCR ReadyMix™ Kit. It contains the Mutant Reverse Transcriptase, Cod Uracil-DNA Glycosylase and Taq DNA polymerase enzymes that are optimised for convenient generation of complimentary DNA and its subsequent amplification in a single tube. The kit is specific for in vitro detection of SARS-CoV-2 RNA, which is extracted from human clinical samples (i.e., nasopharyngeal, and oropharyngeal swabs) from patients suspected of having COVID-19 by healthcare providers. It utilizes the World Health Organization (WHO) recommended primer and probe sets. The kit comes with custom-made Applied Biosystems™ TAQMAN® QSY™ probes. The assay is compatible with Applied Biosystems’s MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit (cat no. A42352). There are no recorded incompatibilities with existing RNA extraction kits.
| Catalogue no | COVRT05001 | COVRT10001 |
| Number of reactions | 500 | 1000 |
| CapeEnzymes ReadyMix™ (consists of mutant reverse transcriptase, UDG-cod and CapeSprint™ Taq DNA polymerase) | 1500 μL | 3000 μL |
| CapeBuffer 10X ReadyMix™ (consists of optimized reaction buffer & dNTPs) | 1750 μL | 3500 μL |
| SARS-CoV-2_N-Gene Primers/Probe ReadyMix™ (Reporter: VIC; Quencher: QSY) | 1200 μL | 2400 μL |
| SARS-CoV-2_S-Gene Primers/Probe ReadyMix™ (Reporter: ABY; Quencher: QSY) | 750 μL | 1500 μL |
| SARS-CoV-2_Human RNaseP_Forward Primers/Probe ReadyMix™ (Reporter: ABY; Quencher: QSY) | 1200 μL | 2400 μL |
| SARS-CoV-2_S-Gene Positive Control | 40 μL | 80 μL |
| SARS-CoV-2_N-Gene Positive Control | 40 μL | 80 μL |
| Nuclease-Free Water | 2000 μL | 4000 μL |